A Turning Point in MASH A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine. By HH Kim January 8, 2026 5 min The Medicine Maker Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Poll Top Institutions Top Thought Leaders